Anti-tumour activity of bisphosphonates in human myeloma cells

C M Shipman, M J Rogers, J F Apperley, R G G Russell, P I Croucher

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Multiple myeloma is a haematological malignancy characterized by an expansion of malignant plasma cells within the bone marrow and is frequently associated with bone disease involving the development of osteolytic bone lesions, pathological fractures, osteoporosis and hypercalcaemia. A class of anti-resorptive drugs known as bisphosphonates have been in use to treat osteoclast-mediated bone diseases for the past 3 decades, and are currently proving effective in the treatment of the bone disease associated with multiple myeloma. Recent studies have suggested that bisphosphonate treatment may also result in an improvement in survival in some patients with multiple myeloma. These effects on survival may reflect an indirect effect of the bisphosphonates on tumour growth, via inhibition of osteoclast activity and hence a reduction in the release of tumour growth factors. However, it is also possible that bisphosphonates may have a direct effect on myeloma cells. In support of this we have demonstrated that bisphosphonates can decrease cell proliferation and induce apoptosis in human myeloma cells in vitro, and this review discusses the possibility that bisphosphonates may have not only an anti-resorptive action, but may also have a direct anti-tumour activity.

Original languageEnglish
Pages (from-to)129-138
Number of pages10
JournalLeukemia
Volume32
Issue number1-2
DOIs
Publication statusPublished - 1998

Keywords

  • multiple myeloma
  • bisphosphonates
  • apoptosis
  • bone disease
  • multiple-myeloma
  • in-vitro
  • bone-resorption
  • induce apoptosis
  • macrophage-like
  • marrow
  • growth
  • cancer
  • malignancies
  • pharmacology

Cite this

Shipman, C. M., Rogers, M. J., Apperley, J. F., Russell, R. G. G., & Croucher, P. I. (1998). Anti-tumour activity of bisphosphonates in human myeloma cells. Leukemia, 32(1-2), 129-138. https://doi.org/10.3109/10428199809059253

Anti-tumour activity of bisphosphonates in human myeloma cells. / Shipman, C M ; Rogers, M J; Apperley, J F ; Russell, R G G ; Croucher, P I .

In: Leukemia, Vol. 32, No. 1-2, 1998, p. 129-138.

Research output: Contribution to journalArticle

Shipman, CM, Rogers, MJ, Apperley, JF, Russell, RGG & Croucher, PI 1998, 'Anti-tumour activity of bisphosphonates in human myeloma cells' Leukemia, vol. 32, no. 1-2, pp. 129-138. https://doi.org/10.3109/10428199809059253
Shipman CM, Rogers MJ, Apperley JF, Russell RGG, Croucher PI. Anti-tumour activity of bisphosphonates in human myeloma cells. Leukemia. 1998;32(1-2):129-138. https://doi.org/10.3109/10428199809059253
Shipman, C M ; Rogers, M J ; Apperley, J F ; Russell, R G G ; Croucher, P I . / Anti-tumour activity of bisphosphonates in human myeloma cells. In: Leukemia. 1998 ; Vol. 32, No. 1-2. pp. 129-138.
@article{29e36d3122ce4dddb17a61993a964eb7,
title = "Anti-tumour activity of bisphosphonates in human myeloma cells",
abstract = "Multiple myeloma is a haematological malignancy characterized by an expansion of malignant plasma cells within the bone marrow and is frequently associated with bone disease involving the development of osteolytic bone lesions, pathological fractures, osteoporosis and hypercalcaemia. A class of anti-resorptive drugs known as bisphosphonates have been in use to treat osteoclast-mediated bone diseases for the past 3 decades, and are currently proving effective in the treatment of the bone disease associated with multiple myeloma. Recent studies have suggested that bisphosphonate treatment may also result in an improvement in survival in some patients with multiple myeloma. These effects on survival may reflect an indirect effect of the bisphosphonates on tumour growth, via inhibition of osteoclast activity and hence a reduction in the release of tumour growth factors. However, it is also possible that bisphosphonates may have a direct effect on myeloma cells. In support of this we have demonstrated that bisphosphonates can decrease cell proliferation and induce apoptosis in human myeloma cells in vitro, and this review discusses the possibility that bisphosphonates may have not only an anti-resorptive action, but may also have a direct anti-tumour activity.",
keywords = "multiple myeloma, bisphosphonates, apoptosis, bone disease, multiple-myeloma, in-vitro, bone-resorption, induce apoptosis, macrophage-like, marrow, growth, cancer, malignancies, pharmacology",
author = "Shipman, {C M} and Rogers, {M J} and Apperley, {J F} and Russell, {R G G} and Croucher, {P I}",
year = "1998",
doi = "10.3109/10428199809059253",
language = "English",
volume = "32",
pages = "129--138",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "1-2",

}

TY - JOUR

T1 - Anti-tumour activity of bisphosphonates in human myeloma cells

AU - Shipman, C M

AU - Rogers, M J

AU - Apperley, J F

AU - Russell, R G G

AU - Croucher, P I

PY - 1998

Y1 - 1998

N2 - Multiple myeloma is a haematological malignancy characterized by an expansion of malignant plasma cells within the bone marrow and is frequently associated with bone disease involving the development of osteolytic bone lesions, pathological fractures, osteoporosis and hypercalcaemia. A class of anti-resorptive drugs known as bisphosphonates have been in use to treat osteoclast-mediated bone diseases for the past 3 decades, and are currently proving effective in the treatment of the bone disease associated with multiple myeloma. Recent studies have suggested that bisphosphonate treatment may also result in an improvement in survival in some patients with multiple myeloma. These effects on survival may reflect an indirect effect of the bisphosphonates on tumour growth, via inhibition of osteoclast activity and hence a reduction in the release of tumour growth factors. However, it is also possible that bisphosphonates may have a direct effect on myeloma cells. In support of this we have demonstrated that bisphosphonates can decrease cell proliferation and induce apoptosis in human myeloma cells in vitro, and this review discusses the possibility that bisphosphonates may have not only an anti-resorptive action, but may also have a direct anti-tumour activity.

AB - Multiple myeloma is a haematological malignancy characterized by an expansion of malignant plasma cells within the bone marrow and is frequently associated with bone disease involving the development of osteolytic bone lesions, pathological fractures, osteoporosis and hypercalcaemia. A class of anti-resorptive drugs known as bisphosphonates have been in use to treat osteoclast-mediated bone diseases for the past 3 decades, and are currently proving effective in the treatment of the bone disease associated with multiple myeloma. Recent studies have suggested that bisphosphonate treatment may also result in an improvement in survival in some patients with multiple myeloma. These effects on survival may reflect an indirect effect of the bisphosphonates on tumour growth, via inhibition of osteoclast activity and hence a reduction in the release of tumour growth factors. However, it is also possible that bisphosphonates may have a direct effect on myeloma cells. In support of this we have demonstrated that bisphosphonates can decrease cell proliferation and induce apoptosis in human myeloma cells in vitro, and this review discusses the possibility that bisphosphonates may have not only an anti-resorptive action, but may also have a direct anti-tumour activity.

KW - multiple myeloma

KW - bisphosphonates

KW - apoptosis

KW - bone disease

KW - multiple-myeloma

KW - in-vitro

KW - bone-resorption

KW - induce apoptosis

KW - macrophage-like

KW - marrow

KW - growth

KW - cancer

KW - malignancies

KW - pharmacology

U2 - 10.3109/10428199809059253

DO - 10.3109/10428199809059253

M3 - Article

VL - 32

SP - 129

EP - 138

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 1-2

ER -